Head-to-head comparisons

BPC-157 and TB-500 are the two most widely discussed recovery peptides, often stacked together in what the biohacking community calls the "Wolverine stack.

Ipamorelin and sermorelin are both growth hormone secretagogues—peptides that stimulate the pituitary gland to release growth hormone—but they do so through different receptor systems.

CJC-1295 and sermorelin are both analogs of growth hormone-releasing hormone (GHRH), but they differ dramatically in half-life and dosing convenience.

Selank and semax are both synthetic peptides developed at the Institute of Molecular Genetics in Russia and approved there as prescription medications.

BPC-157 and GHK-Cu are both regenerative peptides but serve largely different primary applications.

MK-677 (ibutamoren) and ipamorelin are both growth hormone secretagogues that act on the ghrelin receptor, but they differ in administration route, selectivity, and side effect profiles.

PT-141 (bremelanotide) and kisspeptin-10 are both peptides studied for sexual health, but they work through entirely different biological systems.

TB-500 and GHK-Cu are both studied for tissue repair and regeneration, but they differ in structure, primary applications, and evidence base.

Peptides and SARMs (Selective Androgen Receptor Modulators) are frequently discussed in the same fitness and biohacking communities, but they are fundamentally different classes of compounds.

Peptides and anabolic steroids are frequently conflated in fitness discussions, but they are fundamentally different classes of compounds with distinct mechanisms, legal statuses, and risk profiles.

Semaglutide and tirzepatide are the two dominant peptide therapeutics in the weight loss market, generating tens of billions in combined revenue.

Semaglutide and liraglutide are both GLP-1 receptor agonists made by Novo Nordisk, but they represent different generations of the technology.

Tesamorelin and semaglutide both reduce body fat, but they work through entirely different biological pathways.

AOD-9604 and semaglutide both appear in fat loss discussions, but they are vastly different in evidence quality, mechanism, and regulatory status.

BPC-157 and semaglutide are two of the most discussed peptides, but they serve entirely different purposes.

Retatrutide and tirzepatide represent two generations of multi-receptor agonist therapy for obesity.

Orforglipron and semaglutide both target the GLP-1 receptor for weight loss and diabetes, but they represent fundamentally different molecular approaches.

CagriSema and tirzepatide represent two different dual-mechanism strategies for obesity.

Survodutide and semaglutide both activate the GLP-1 receptor, but survodutide adds glucagon receptor agonism to increase energy expenditure and target liver fat.

Liraglutide and tirzepatide represent different generations of incretin therapy.

Tirzepatide and dulaglutide are both made by Eli Lilly and are both weekly GLP-1 pathway injectables, but tirzepatide (Mounjaro/Zepbound) adds GIP receptor agonism for dramatically improved efficacy.

AOD-9604 and tesamorelin are both discussed in fat loss contexts with connections to the growth hormone axis, but they differ dramatically in evidence quality and regulatory status.

Retatrutide and semaglutide represent the cutting edge versus the current standard in GLP-1-based obesity therapy.

Semaglutide and exenatide are both GLP-1 receptor agonists, but they represent different eras of GLP-1 drug development.

MK-677 and sermorelin both aim to increase growth hormone levels but through completely different receptor systems and routes of administration.

Hexarelin and ipamorelin are both ghrelin receptor agonists that stimulate growth hormone release, but they differ significantly in potency, selectivity, and side effect profiles.

GHRP-2 and GHRP-6 are two of the original synthetic growth hormone releasing peptides, both acting on the ghrelin receptor to stimulate GH release from the pituitary.

Sermorelin and tesamorelin are both analogs of growth hormone-releasing hormone (GHRH) that stimulate the pituitary to release GH.

CJC-1295 and tesamorelin are both GHRH analogs that stimulate pituitary GH release, but they occupy different positions in the research-to-clinical spectrum.

MK-677 and CJC-1295 both increase growth hormone levels but through entirely different receptor systems and administration routes.

GHRP-6 and ipamorelin both stimulate growth hormone release through the ghrelin receptor pathway, but they represent different generations of GH secretagogue development.

BPC-157 and MGF (Mechano Growth Factor) are both used in recovery contexts, but they serve fundamentally different biological roles.

GHK-Cu and epithalon are both discussed in anti-aging contexts but target entirely different biological mechanisms.

Selank and N-Acetyl Semax Amidate (NASA) are both Russian-developed nootropic peptides, but they serve different cognitive functions.

Semax and noopept are both Russian-developed nootropic compounds frequently compared in cognitive enhancement discussions.

Dihexa and semax are both nootropic peptides with neurotrophic properties, but they differ dramatically in potency, mechanism, and evidence maturity.

GHK-Cu and Matrixyl (palmitoyl pentapeptide-4) are two of the most prominent peptides in cosmetic skincare, both promoting collagen production but through different mechanisms.

Thymosin alpha-1 and thymalin are both thymus-derived immune-modulating peptides, but they differ fundamentally in characterization and evidence quality.

SNAP-8 (acetyl octapeptide-3) and Argireline (acetyl hexapeptide-3) are both cosmetic peptides that reduce expression wrinkles by inhibiting the SNARE complex involved in neuromuscular signaling.

BPC-157 and ipamorelin are two of the most popular peptides in the biohacking community, but they serve entirely different purposes.

TB-500 and IGF-1 LR3 are both used in recovery and growth contexts, but they serve fundamentally different biological roles.

CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide into a single weekly injection, while semaglutide is the standalone GLP-1 receptor agonist sold as Ozempic and Wegovy.

Orforglipron is Eli Lilly's oral, once-daily, non-peptide GLP-1 receptor agonist, while tirzepatide (Mounjaro/Zepbound) is the company's injectable dual GIP/GLP-1 receptor agonist.

Mazdutide is a dual GLP-1 and glucagon receptor agonist modeled on oxyntomodulin, approved in China as Xinermei and in US Phase 2 trials.

Mazdutide and tirzepatide are both dual-receptor agonists designed for weight loss and metabolic disease, but they target different receptor pairs.

Retatrutide and survodutide represent the next generation of multi-receptor obesity therapeutics, both in Phase 3 development.

Semaglutide is the most commercially successful GLP-1 receptor agonist, with over $20 billion in annual revenue and extensive clinical data.

Ipamorelin and GHRP-2 are both growth hormone secretagogues that act on the ghrelin receptor (GHSR-1a) to stimulate pulsatile GH release from the pituitary.

Ipamorelin and tesamorelin both stimulate growth hormone release from the pituitary gland, but they act through different receptor systems and have very different regulatory statuses.

IGF-1 DES and IGF-1 LR3 are both modified forms of insulin-like growth factor 1, but they represent fundamentally different engineering approaches.

MGF (Mechano Growth Factor) and PEG-MGF are the native and PEGylated forms of the same IGF-1 splice variant (IGF-1Ec) produced in muscle tissue after mechanical loading.

Melanotan II and PT-141 (bremelanotide) share a common origin — both are synthetic analogs of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona.

Epithalon and FOXO4-DRI represent two distinct approaches to aging biology.

Humanin and MOTS-c are both mitochondrial-derived peptides (MDPs), encoded within the mitochondrial genome rather than nuclear DNA.

MOTS-c and SS-31 (elamipretide) both target mitochondrial biology but from entirely different angles.

Teriparatide and abaloparatide are the two bone-anabolic peptide injectables FDA-approved for severe postmenopausal osteoporosis and men at high fracture risk.

GnRH agonists and GnRH antagonists act on the same pituitary receptor but produce opposite initial effects, and that contrast defines the entire clinical decision tree for gonadotropin suppression.

Desmopressin and vasopressin are close chemical cousins with strikingly different clinical footprints.

Bortezomib and carfilzomib are the two FDA-approved 20S proteasome inhibitors that define modern multiple myeloma therapy.

Octreotide, lanreotide, and pasireotide are the three somatostatin analogs that dominate the treatment of acromegaly, neuroendocrine tumors (NETs), and — for pasireotide — Cushing's disease.

Gramicidin and polymyxin B are two of the oldest and most clinically important peptide antibiotics.